How should pharma respond to the Inflation Reduction Act? The IDI spoke to two market access experts, Jim Kenney and and Diane Petrone, for some advice.
When President Biden signed the Inflation Reduction Act into law earlier this year, he set the stage for some of the biggest changes the pharmaceutical industry has seen in years. So how should pharma prepare for the IRA?
Diane Petrone and Jim Kenney, principal consultants with Valuate Health, join The IDI to discuss what they're hearing from pharma clients about the IRA; which aspects of the IRA will have the biggest impact on pharma; why removing some drug rebate calculations (as laid out in the IRA) is a big deal; and more.
Follow Valuate on LinkedIn or visit us at ValuateHealth.com.